Screener
Adaptive Biotechnologies ADPT Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206546
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Current portion of operating lease liabilities | 8,513 | 8,920 |
| Current portion of deferred revenue | 49,397 | 45,194 |
| Current portion of revenue interest liability, net | 5,804 | 4,642 |
| Total current liabilities | 87,011 | 89,915 |
| Long-term liabilities | ||
| Operating lease liabilities, less current portion | 69,115 | 70,228 |
| Deferred revenue, less current portion | 807 | 1,006 |
| Revenue interest liability, net, less current portion | 124,749 | 126,566 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Adaptive Biotechnologies's total current liabilities?
- Adaptive Biotechnologies (ADPT) reported total current liabilities of $87.01M in Q1 2026.
- How has Adaptive Biotechnologies's total current liabilities changed year-over-year?
- Adaptive Biotechnologies's total current liabilities decreased by 0.9% year-over-year, from $87.81M to $87.01M.
- What is the long-term trend for Adaptive Biotechnologies's total current liabilities?
- Over 5 years (2020 to 2025), Adaptive Biotechnologies's total current liabilities has grown at a -3.1% compound annual growth rate (CAGR), from $105.2M to $89.92M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Adaptive Biotechnologies's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude